Scarica l'app Stockscreener
8.05
1.11%
-0.09
Dopo l'orario di chiusura:
8.06
0.010
+0.12%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NVAX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$8.14
Aprire:
$8.13
Volume 24 ore:
2.27M
Relative Volume:
0.55
Capitalizzazione di mercato:
$1.33B
Reddito:
$596.34M
Utile/perdita netta:
$-87.84M
Rapporto P/E:
-13.47
EPS:
-0.5975
Flusso di cassa netto:
$-97.62M
1 W Prestazione:
+1.26%
1M Prestazione:
-4.39%
6M Prestazione:
-7.47%
1 anno Prestazione:
-14.63%
Intervallo 1D:
$7.915
$8.13
Intervallo di 1 settimana:
$7.695
$8.23
Portata 52W:
$6.20
$11.97
Novavax Inc Stock (NVAX) Company Profile
Nome
Novavax Inc
Settore
Industria
Telefono
240-268-2000
Indirizzo
21 FIRSTFIELD RD, GAITHERSBURG, MD
Compare NVAX vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
8.05 | 1.31B | 596.34M | -87.84M | -97.62M | -0.5975 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-08-28 | Ripresa | H.C. Wainwright | Buy |
| 2025-08-20 | Downgrade | BofA Securities | Neutral → Underperform |
| 2025-06-17 | Iniziato | Citigroup | Sell |
| 2025-02-28 | Iniziato | BTIG Research | Buy |
| 2024-07-30 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-05-10 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-05-10 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-08-09 | Aggiornamento | B. Riley Securities | Neutral → Buy |
| 2023-04-20 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-03-01 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2023-01-09 | Reiterato | B. Riley Securities | Buy |
| 2022-12-30 | Reiterato | H.C. Wainwright | Buy |
| 2022-12-02 | Iniziato | Jefferies | Hold |
| 2022-09-22 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-05-20 | Iniziato | BofA Securities | Underperform |
| 2022-02-23 | Reiterato | B. Riley Securities | Buy |
| 2022-02-22 | Ripresa | Jefferies | Buy |
| 2022-01-21 | Iniziato | Cowen | Outperform |
| 2021-05-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-12-14 | Iniziato | Jefferies | Buy |
| 2020-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-05 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-08-05 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| 2020-07-16 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2020-06-29 | Reiterato | B. Riley FBR | Buy |
| 2020-06-29 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2020-05-28 | Reiterato | B. Riley FBR | Buy |
| 2020-05-12 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-30 | Reiterato | H.C. Wainwright | Buy |
| 2019-11-27 | Ripresa | B. Riley FBR | Buy |
| 2019-08-14 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-28 | Downgrade | Piper Jaffray | Overweight → Underweight |
| 2018-12-18 | Iniziato | Ladenburg Thalmann | Buy |
| 2018-12-11 | Iniziato | Oppenheimer | Outperform |
| 2018-11-26 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2018-09-21 | Aggiornamento | JP Morgan | Underweight → Overweight |
| 2018-03-29 | Aggiornamento | Seaport Global Securities | Neutral → Buy |
Mostra tutto
Novavax Inc Borsa (NVAX) Ultime notizie
Novavax, Inc. (NASDAQ:NVAX) Given Consensus Rating of "Hold" by Analysts - marketbeat.com
(NVAX) Volatility Zones as Tactical Triggers - Stock Traders Daily
NVAX Stock Rises Overnight Ahead Of Q4 Print With Pfizer Tailwinds — Analyst Warns Of 20% Crash - Stocktwits
Novavax Q4 Earnings Preview: Wall Street Expects Wider Losses Amid Diversification Efforts - Stocktwits
Novavax Inc. stock underperforms Friday when compared to competitors - MarketWatch
Novavax Swings To Profit In Q4 Fueled By Nuvaxovid-Linked Revenue - Stocktwits
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
How Novavax’s (NVAX) Earnings Slide and New Share Shelf Will Impact Investors - webull.com
Novavax Stock Hits Over 1-Year High: Is Sanofi’s Flu-COVID Shot The Post-Pandemic Growth Driver? - Stocktwits
NVAX Stock Is Rising Even After A Revenue Collapse – Here’s The Catch - Stocktwits
Bank of America Corp DE Cuts Stock Holdings in Novavax, Inc. $NVAX - marketbeat.com
Novavax, Inc. (NVAX) Stock Analysis: Growth Potential Amidst A 77% Upside - DirectorsTalk Interviews
Novavax, Inc. (NVAX) Options Chain - Yahoo! Finance Canada
Novavax (NASDAQ:NVAX) Lowered to Hold Rating by Zacks Research - MarketBeat
Novavax (NVAX) Gets a Sell from Bank of America Securities - The Globe and Mail
Renaissance Technologies LLC Invests $4.05 Million in Novavax, Inc. $NVAX - marketbeat.com
Novavax (NVAX) Stock Faces Revenue Slump As Losses Deepen - Sahm
NVAX Q2 Earnings & Sales Beat Estimates, '26 Sales Outlook Raised - Yahoo Finance
State Street Corporation (NYSE: STT) discloses 7.1% ownership of Novavax - Stock Titan
Novavax, Inc. Stock 12‑Month Price Target Cut to $13.75, Implies 78% Upside - TradingView
Novavax Q2 2026 slides: partnership pivot drives revenue beat By Investing.com - Investing.com Nigeria
NVAX SWOT Analysis: Financial Challenges and Opportunities Revea - GuruFocus
Novavax Q2 Earnings Call Highlights - MarketBeat
Novavax (NASDAQ:NVAX) Posts Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat
NVAX Looks 107.0% Overvalued on GF Value™ - GuruFocus
Novavax Inc (NVAX) (Q2 2026) Earnings Call Highlights: Matrix-M - GuruFocus
Novavax Inc (NVAX) (Q2 2026) Earnings Call Highlights: Matrix-M Momentum Drives Revenue ... - Yahoo Finance
Novavax Q2 2026 Earnings Call Transcript - MarketBeat
Novavax, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:NVAX) 2026-08-06 - Seeking Alpha
NVAX Stock Holds Steady As Novavax Lifts Revenue Outlook On Licensing Pivot — Retail Eyes Buyout, More Partnership Deals - Yahoo Finance
Novavax raises annual revenue forecast as licensing bets offset weak vaccine demand - kfgo.com
Novavax Q2 2026 slides: partnership pivot drives revenue beat - Investing.com
Novavax Raises 2026 Revenue Outlook After Q2 Earnings Beat - citybiz
NVAX: Q2 2026 revenue reached $57M, with strong Matrix-M growth and major partnership milestones ahead - TradingView
Earnings call transcript: Novavax beats Q2 2026 estimates, lifts revenue outlook - Investing.com
Is Novavax Inc (NVAX) Under Pressure After Q2 Earnings Miss? EPS - GuruFocus
Novavax, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Novavax tops forecasts and raises revenue outlook as Sanofi collaboration progresses - Yahoo Finance
Novavax (NVAX) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Are Medical Stocks Lagging Novavax (NVAX) This Year? - Yahoo Finance
NVAX: Q2 2026 product sales rose 76% YoY, but total revenue fell sharply as milestone payments declined - TradingView
Novavax, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Earnings Flash (NVAX) Novavax Posts Q2 Net Loss of $0.32 a Share, vs. FactSet Est. of $0.38 Loss - marketscreener.com
Novavax (NASDAQ:NVAX) Exceeds Q2 CY2026 Expectations - Yahoo Finance
Novavax raises 2026 outlook after Q2 beat (NVAX:NASDAQ) - Seeking Alpha
NOVAVAX INC NOVAVAX ORD SHS (0A3S.L) Q2 FY2026 earnings call transcript - Yahoo Finance
Novavax lifts annual revenue forecast as licensing bets offset weak vaccine demand - WTVB
Novavax reports Q2 2026 revenue $57M, narrows R&D+SG&A guidance and raises 2026 revenue framework - TradingView
Novavax Q2 Revenue Falls 76 Percent to $57 Million - Quiver Quantitative
Novavax: Q2 Earnings Snapshot - Yahoo Finance
Novavax (Nasdaq: NVAX) Q2 revenue $57M, swings to $53M loss - Stock Titan
Novavax Inc Azioni (NVAX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):